Today's Daily Dose brings you news about updated results from Celgene's TRANSCEND study; Epizyme's mesothelioma trial results; FDA approval of lower dose of OLUMIANT; Jazz Pharma's phase III TONES 5 study results, and early termination of Sellas' Phase 2b NeuVax study in combination with Herceptin in HER2 1+/2+ breast cancer patients.